Did Medtronic beat expectations and why did it raise guidance?

Management said revenue outperformance flowed through to earnings and that adjusted EPS was ahead of expectations. The company raised its organic revenue growth guidance to 4.5%-5% and non-GAAP EPS guidance to $5.42-$5.50, citing new product introductions and the investments supporting them.

Is the 36% increase in GAAP EPS a sign of strong underlying earnings growth?

Not entirely. GAAP EPS growth reflects a much lower tax provision ($220M vs. $400M a year earlier, which included a prior-year tax adjustment) and $157M of non-operating income. On a non-GAAP basis, net income was flat and EPS rose 3%, which better reflects operating trends.

How significant is the Italian payback accrual?

The incremental accrual totaled $90M in the quarter and was excluded from organic growth and non-GAAP results. It relates to rulings on prior years since 2015 and is a one-time item, but it reduces reported Other revenue and GAAP profitability in the quarter.

What are the main risks to the outlook?

Currency is a material headwind, estimated at about -5% to EPS for FY25. Medical Surgical growth is weak at +1.0% organic, and free cash flow is declining as capex and buybacks rise. The company also has higher debt, with long-term debt up to $26.3B from $23.9B.

MDT 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed August 20, 2024. Cited figures are marked; the original filing is the authoritative source.

Medtronic plc reported first quarter fiscal 2025 results (quarter ended July 26, 2024) that beat expectations on the top line and led management to raise its FY25 guidance.

Reported revenue was $7.915 billion^a, up 2.8%, and organic growth was 5.3%, with Cardiovascular (+6.9% organic), Neuroscience (+5.3%) and Diabetes (+12.6%) leading. Medical Surgical was weaker at +1.0% organic. GAAP diluted EPS was $0.80, up 36%, but this is flattered by a $142 million Italian payback accrual and a tax-related swing: GAAP net income rose 32% while non-GAAP net income was flat at $1.592 billion.

Non-GAAP diluted EPS was $1.23^b, up 3% (8% in constant currency), with a roughly 6-cent currency headwind. Management raised FY25 organic revenue growth guidance to 4.5%-5% (from 4%-5%) and non-GAAP diluted EPS guidance to $5.42-$5.50 (from $5.40-$5.50). Including Other revenue and currency, adjusted revenue growth is guided to 3.4%-4.3%, and EPS growth to 4%-6% after an estimated 5% currency headwind.

Cash flow was softer: free cash flow fell to $466 million^c from $521 million as capital expenditures rose to $520 million, and the company repurchased $2.5 billion of shares while issuing $3.2 billion of long-term debt, which pushed long-term debt up to $26.3 billion. The company is led on an interim basis by CFO Gary Corona, which investors should note. For investors, the key takeaways are solid organic growth driven by new product launches (Evolut FX+, PulseSelect, Inceptiv, Percept RC, MiniMed 780G, Simplera), a modest guidance raise, and quality-of-earnings caveats: reported GAAP gains were partly driven by tax and non-operating items, and the Italian accrual is a one-time charge affecting Other revenue and the quarter's margins.

02—Key points

Key Highlights

Reported revenue of $7.915B rose 2.8%; organic growth was 5.3%, with Cardiovascular up 6.9% organic, Neuroscience up 5.3%, and Diabetes up 12.6%.
FY25 organic revenue growth guidance raised to 4.5%-5% (from 4%-5%); including Other revenue and FX, adjusted revenue growth is 3.4%-4.3%.
Non-GAAP diluted EPS of $1.23 rose 3% (8% constant currency), with about a 6-cent FX headwind; FY25 non-GAAP EPS guidance raised to $5.42-$5.50 from $5.40-$5.50.
GAAP diluted EPS of $0.80 (up 36%) was boosted by a lower tax provision and non-operating gains; non-GAAP net income was flat at $1.592B.
Q1 included a $90M Italian payback accrual (in Other revenue and non-GAAP exclusions) tied to July 22, 2024 Constitutional Court of Italy rulings.
Free cash flow declined to $466M from $521M as capex rose to $520M; the company repurchased $2.5B of shares and issued $3.2B of long-term debt.
Growth drivers include Micra and PulseSelect PFA in cardiac, Evolut FX+ TAVR (limited U.S. launch), Percept RC/Inceptiv in neuromodulation, and MiniMed 780G AID with Simplera CGM; Medical Surgical lagged at +1.0% organic.

03—Questions

Frequently Asked Questions

Did Medtronic beat expectations and why did it raise guidance?
Management said revenue outperformance flowed through to earnings and that adjusted EPS was ahead of expectations. The company raised its organic revenue growth guidance to 4.5%-5% and non-GAAP EPS guidance to $5.42-$5.50, citing new product introductions and the investments supporting them.
Is the 36% increase in GAAP EPS a sign of strong underlying earnings growth?
Not entirely. GAAP EPS growth reflects a much lower tax provision ($220M vs. $400M a year earlier, which included a prior-year tax adjustment) and $157M of non-operating income. On a non-GAAP basis, net income was flat and EPS rose 3%, which better reflects operating trends.
How significant is the Italian payback accrual?
The incremental accrual totaled $90M in the quarter and was excluded from organic growth and non-GAAP results. It relates to rulings on prior years since 2015 and is a one-time item, but it reduces reported Other revenue and GAAP profitability in the quarter.
What are the main risks to the outlook?
Currency is a material headwind, estimated at about -5% to EPS for FY25. Medical Surgical growth is weak at +1.0% organic, and free cash flow is declining as capex and buybacks rise. The company also has higher debt, with long-term debt up to $26.3B from $23.9B.

04—Continue

← View all 8-K filings